866-997-4948(US-Canada Toll Free)

Swine Influenza - Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Aug 2012

Category :

Wine

No. of Pages : 201 Pages


Swine Influenza Pipeline Review, H2 2012


Global Markets Directs, \'Swine Influenza Pipeline Review, H2 2012\', provides an overview of the Swine Influenza therapeutic pipeline. This report provides information on the therapeutic development for Swine Influenza, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Swine Influenza. \'Swine Influenza Pipeline Review, H2 2012\' is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Swine Influenza.
  • A review of the Swine Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Swine Influenza pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Swine Influenza.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Swine Influenza pipeline depth and focus of Swine Influenza therapeutics. 
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Swine Influenza Therapeutic Products under Development, Key Players in Swine Influenza Therapeutics, Swine Influenza Pipeline Overview, Swine Influenza Pipeline, Swine Influenza Pipeline Assessment
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Swine Influenza Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Swine Influenza 10
Swine Influenza Therapeutics under Development by Companies 12
Swine Influenza Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Pre-Clinical Stage Products 21
Comparative Analysis 21
Swine Influenza Therapeutics Products under Development by Companies 22
Swine Influenza Therapeutics Products under Investigation by Universities/Institutes 26
Companies Involved in Swine Influenza Therapeutics Development 28
Baxter International Inc. 28
Johnson & Johnson 29
Vical Incorporated 30
GlaxoSmithKline plc 31
Inovio Biomedical Corporation 32
Celltrion, Inc. 33
Novartis AG 34
Novavax, Inc. 35
CEL-SCI Corporation 36
AVI BioPharma Inc. 37
Crucell N.V. 38
OPKO Health, Inc. 39
Medicago Inc. 40
NovaBay Pharmaceuticals, Inc. 41
XOMA Ltd. 42
Lipoxen PLC 43
Green Cross Corporation 44
Synairgen plc 45
Antigen Express, Inc. 46
Colby Pharmaceutical Company 47
Marinomed Biotechnologie GmbH 48
LigoCyte Pharmaceuticals, Inc. 49
TechnoVax, Inc. 50
AlphaVax, Inc. 51
Theraclone Sciences, Inc. 52
REPLICor Inc. 53
Protein Sciences Corporation 54
Etubics Corporation 55
iBio, Inc. 56
Avir Green Hills Biotechnology AG 57
Sirnaomics, Inc. 58
Vaxart, Inc. 59
NasVax Ltd. 60
ImmuneRegen BioSciences, Inc. 61
Vivaldi Biosciences Inc. 62
Vaxine Pty Ltd 63
Swine Influenza Therapeutics Assessment 64
Assessment by Monotherapy Products 64
Assessment by Combination Products 65
Assessment by Route of Administration 66
Assessment by Molecule Type 69
Drug Profiles 72
CR6261 - Drug Profile 72
Homspera - Drug Profile 74
Flu Vaccine - Drug Profile 76
REP-9AC - Drug Profile 77
H1N1 Vaccine - Drug Profile 79
Vaccine for Pandemic Influenza (H1 & H5) - Drug Profile 81
NVC-612 - Drug Profile 82
DeltaFLU - Drug Profile 83
Liposomal Influenza Vaccine - Drug Profile 84
PanBlok - Drug Profile 85
H1N1 Plasma - Drug Profile 87
Live Attenuated Influenza Vaccine - Drug Profile 88
Interferon Beta Programme - Drug Profile 89
GSK2340269A - Drug Profile 91
H1N1 Influenza Vaccine - Drug Profile 93
GSK2340272A - Drug Profile 95
H1N1 Influenza Vaccine - Drug Profile 97
Recombinant HIN1 Swine Influenza Vaccine - Drug Profile 98
VRC-FLUDNA057-00-VP - Drug Profile 99
TVX004 - Drug Profile 100
GSK2340273A - Drug Profile 101
STP-702 - Drug Profile 103
F10 Antibody Program - Drug Profile 104
TVX003 - Drug Profile 105
TVX002 - Drug Profile 106
AVI-7100 - Drug Profile 107
Inactivated H1N1 Vaccine + AS03 - Drug Profile 108
Inactivated H1N1 Vaccine - Drug Profile 109
Pandemic Vaccine 1 - Drug Profile 111
Pandemic Vaccine 10 - Drug Profile 113
Pandemic Vaccine 2 - Drug Profile 115
Pandemic Vaccine 5 - Drug Profile 117
Pandemic Vaccine 6 - Drug Profile 119
Pandemic Vaccine 9 - Drug Profile 121
Pandemic Vaccine 11 - Drug Profile 123
Pandemic Vaccine 12 - Drug Profile 124
Pandemic Vaccine 13 - Drug Profile 126
Non-Adjuvanted A(H1N1) Influenza Vaccine - Drug Profile 127
Adjuvanted H1N1 Influenza Virus Vaccine - Drug Profile 128
GSK2340273A + FluLaval - Drug Profile 130
Inactivated Split-virion Influenza A(H1N1) Vaccine GC1116 - Drug Profile 131
HAC1 Vaccine - Drug Profile 132
MF59-eH1N1 Influenza Vaccine - Drug Profile 134
H1N1 Pandemic Influenza Vaccine + Seasonal Trivalent Influenza Vaccine - Drug Profile 135
GSK2340272A + Fluarix - Drug Profile 136
Infergen - Drug Profile 138
Monovalent A/H1N1 Influenza Vaccine - Drug Profile 139
H1N1 2009 VLP Vaccine - Drug Profile 141
Influenza VLP Vaccine - Drug Profile 143
Pandemic H1N1 Vaccine - Drug Profile 144
LEAPS-H1N1-DC - Drug Profile 145
Iota-Carrageenan - Drug Profile 146
Fluad - Drug Profile 147
Focetria - Drug Profile 148
Pandemic Influenza Program - Drug Profile 149
H1N1 Vaccine - Drug Profile 150
Flufirvitide-3 - Drug Profile 152
Trimeric Aichi HA Vaccine - Drug Profile 153
JVRS-100 + Universal Influenza Vaccine - Drug Profile 154
Influenza Vaccine - Drug Profile 156
TCN-032 - Drug Profile 157
Universal Influenza Vaccine - Drug Profile 159
Universal Influenza Vaccine - Drug Profile 160
Flu-mAb - Drug Profile 162
INO-3401 - Drug Profile 163
AEA35p - Drug Profile 165
INO-3605 - Drug Profile 166
INO-3609 - Drug Profile 168
INO-3605 + INO-3609 - Drug Profile 170
H1N1 Influenza Vaccine - Drug Profile 172
IVACFLU - Drug Profile 174
Swine Influenza Therapeutics Drug Profile Updates 175
Swine Influenza Therapeutics Discontinued Products 186
Swine Influenza Therapeutics - Dormant Products 187
Swine Influenza Product Development Milestones 188
Featured News & Press Releases 188

Appendix 195
Methodology 195
Coverage 195
Secondary Research 195
Primary Research 195
Expert Panel Validation 195
Contact Us 196
Disclaimer 196

List of Table


Number of Products Under Development for Swine Influenza, H2 2012 15
Products under Development for Swine Influenza Comparative Analysis, H2 2012 16
Number of Products under Development by Companies, H2 2012 18
Number of Products under Development by Companies, H2 2012 (Contd..1) 19
Number of Products under Development by Companies, H2 2012 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H2 2012 22
Comparative Analysis by Late Stage Development, H2 2012 23
Comparative Analysis by Mid Clinical Stage Development, H2 2012 24
Comparative Analysis by Early Clinical Stage Development, H2 2012 25
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 26
Products under Development by Companies, H2 2012 27
Products under Development by Companies, H2 2012 (Contd..1) 28
Products under Development by Companies, H2 2012 (Contd..2) 29
Products under Development by Companies, H2 2012 (Contd..3) 30
Products under Investigation by Universities/Institutes, H2 2012 31
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 32
Baxter International Inc., H2 2012 33
Johnson & Johnson, H2 2012 34
Vical Incorporated, H2 2012 35
GlaxoSmithKline plc, H2 2012 36
Inovio Biomedical Corporation, H2 2012 37
Celltrion, Inc., H2 2012 38
Novartis AG, H2 2012 39
Novavax, Inc., H2 2012 40
CEL-SCI Corporation, H2 2012 41
AVI BioPharma Inc., H2 2012 42
Crucell N.V., H2 2012 43
OPKO Health, Inc., H2 2012 44
Medicago Inc., H2 2012 45
NovaBay Pharmaceuticals, Inc., H2 2012 46
XOMA Ltd., H2 2012 47
Lipoxen PLC, H2 2012 48
Green Cross Corporation, H2 2012 49
Synairgen plc, H2 2012 50
Antigen Express, Inc., H2 2012 51
Colby Pharmaceutical Company, H2 2012 52
Marinomed Biotechnologie GmbH, H2 2012 53
LigoCyte Pharmaceuticals, Inc., H2 2012 54
TechnoVax, Inc., H2 2012 55
AlphaVax, Inc., H2 2012 56
Theraclone Sciences, Inc., H2 2012 57
REPLICor Inc., H2 2012 58
Protein Sciences Corporation, H2 2012 59
Etubics Corporation, H2 2012 60
iBio, Inc., H2 2012 61
Avir Green Hills Biotechnology AG, H2 2012 62
Sirnaomics, Inc., H2 2012 63
Vaxart, Inc., H2 2012 64
NasVax Ltd., H2 2012 65
ImmuneRegen BioSciences, Inc., H2 2012 66
Vivaldi Biosciences Inc., H2 2012 67
Vaxine Pty Ltd, H2 2012 68
Assessment by Monotherapy Products, H2 2012 69
Assessment by Combination Products, H2 2012 70
Assessment by Stage and Route of Administration, H2 2012 73
Assessment by Stage and Molecule Type, H2 2012 76
Swine Influenza Therapeutics Drug Profile Updates 180
Swine Influenza Therapeutics Discontinued Products 191
Swine Influenza Therapeutics Dormant Products 192

List of Chart


Number of Products under Development for Swine Influenza, H2 2012 15
Products under Development for Swine Influenza - Comparative Analysis, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 21
Late Stage Products, H2 2012 23
Mid Clinical Stage Products, H2 2012 24
Early Clinical Stage Products, H2 2012 25
Pre-Clinical Stage Products, H2 2012 26
Assessment by Monotherapy Products, H2 2012 69
Assessment by Combination Products, H2 2012 70
Assessment by Route of Administration, H2 2012 71
Assessment by Stage and Route of Administration, H2 2012 72
Assessment by Molecule Type, H2 2012 74
Assessment by Stage and Molecule Type, H2 2012 75

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *